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ABSTRACT
Type 2 diabetes is associated with a high
prevalence of comorbidities resulting from
hypertension, dyslipidemia, and
hyperglycemia. Inadequate management of
these risk factors will eventually result in
detrimental health consequences. Thus, the
effect of a drug on factors such as weight,
cardiovascular (CV) risk factors, and adherence
is important to consider. A review was
undertaken of the recent medical literature
describing the extraglycemic characteristics of
the two classes of incretin-based therapies—
glucagon-like peptide-1 receptor agonists (GLP-
1RA) and dipeptidyl peptidase-4 (DPP-4)
inhibitors. PubMed searches were performed to
identify published data on incretin therapies
that describe their effects on CV risk factors, CV
events, and factors related to medication
adherence. The maintenance or loss of weight
associated with the use of GLP-1RAs and DPP-4
inhibitors is well described in the medical
literature. These agents also appear to be
associated with a modest decrease in blood
pressure and a reduced risk of CV events. In
addition, several characteristics of incretin
therapies may improve rates of medication
adherence, such as generally favorable
tolerability profiles (particularly with DPP-4
inhibitors), the availability of formulations
that simplify treatment regimens, and a low
risk for hypoglycemia. The literature on incretin
therapies describes a number of clinical
characteristics that are relevant to the
management of extraglycemic risk factors. As
part of a holistic treatment strategy, these
properties constitute important considerations
for tailoring therapy to individual patients with
type 2 diabetes.
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INTRODUCTION
The high prevalence of comorbidities
associated with type 2 diabetes exerts a
significant socioeconomic burden on the US
healthcare system. For example, diabetes is the
leading cause of end-stage renal disease [1].
One retrospective study of [91,000 patient
records reported an incidence of chronic
kidney disease of *15% in individuals with
both type 2 diabetes and hypertension,
compared with only 1.1% and 1.5% in
patients with diabetes or hypertension alone,
respectively [2]. Diabetes is also a leading cause
of blindness in US adults. A recent pooled
analysis of data from more than 23,000 patients
reported that the prevalence of diabetic
retinopathy may be as high as 35% [3].
Approximately 7 million patients with
diabetes had retinal disease in 2005, and it
has been predicted that this number will
increase to 19 million by the year 2050 [4].
Against this background, physicians must
take into consideration a complex set of
variables when discussing treatment options
with patients who have type 2 diabetes. In the
current era of medical research, the clinical and
pharmacologic characteristics of antidiabetic
agents are being evaluated in greater depth
than just a few decades ago and, as a result, our
understanding of these medicines now extends
far beyond their role in glycemic control.
While the effects of a drug on factors such as
weight, cardiovascular (CV) risk, and
medication adherence were once considered
secondary to the efficacy of the drug for
reducing blood glucose, now many patients
and physicians consider such factors when
choosing medications to meet agreed upon
therapy goals. In this regard, incretin-based
therapies have demonstrated a favorable set of
clinical characteristics that are well suited to
this type of holistic approach to the
management of type 2 diabetes. The aim of
this article is to review the recent medical
literature describing such characteristics for
the two classes of incretin-based therapies—
glucagon-like peptide-1 receptor agonists (GLP-
1RA) and dipeptidyl peptidase-4 (DPP-4)
inhibitors.
MATERIALS AND METHODS
PubMed searches were conducted for literature
describing the extraglycemic effects of incretin-
based therapies. The following terms were used
to search among English language publication
titles in the PubMed database: (incretin[ti] OR
glp-1[ti] OR exenatide[ti] OR liraglutide[ti] OR
(glucagon[ti] AND peptide[ti])); (dipeptidyl[ti]
OR dpp-4[ti] OR sitagliptin[ti] OR saxagliptin[ti]
OR vildagliptin[ti] OR linagliptin[ti]); (tolerab*
OR [effect* AND side OR adverse]) AND
(discontin* [ti] OR adher* [ti] OR non-adher*
[ti] OR nonadher* [ti] OR complian* [ti]);
(weight [ti] OR bmi [ti] OR body mass [ti]);
(cardiovasc*[ti] OR lipid*[ti] OR pressure[ti] OR
cholesterol[ti]). When needed for more targeted
searches, results were restricted to clinical trials
or were expanded to title/abstract using the
appropriate PubMed limiters. Initial literature
searches were conducted from 30 August to 18
December 2012, with additional searches on
specific topics as required to update the review.
No date restrictions were specified. PubMed
abstracts were qualitatively reviewed and
individually selected based on their relevance
to the review topic. Articles that were
considered relevant based on an assessment of
an abstract were obtained and further
evaluated, with attention to references cited
for further resources.




In obese individuals, the risk of developing type
2 diabetes is elevated *sevenfold relative to
those with normal body weight [5]. The
presence of diabetes and obesity elevates the
risk (individually and in combination) of
numerous complications and comorbidities,
including CV disease, hypertension, and
stroke. Cardiovascular disease alone is
responsible for *65% of deaths in patients
with type 2 diabetes [6]. Therefore, given that
most individuals with type 2 diabetes are obese,
weight reduction is a key strategy to reduce
morbidity and mortality.
The Action for Health in Diabetes (Look
AHEAD) study was designed to provide a
quantitative assessment of the association
between modest weight reduction in
overweight/obese patients with type 2 diabetes
and the incidence of severe CV events (heart
disease, stroke, and CV-related deaths). The
study began in 2001 and was scheduled to
complete in 2014. In the first year of Look
AHEAD, patients participating in intensive
lifestyle intervention (N = 2,503) lost *7–9%
of body weight [7]. This was associated with a
25–33 mg/dL decrease in serum triglycerides
(TG) and a 5–8 mmHg reduction in systolic
blood pressure (SBP). As a reference for the
clinical relevance of this magnitude of blood
pressure (BP) reduction, in the United Kingdom
Prospective Diabetes Study (UKPDS), each
10 mmHg reduction in SBP was associated
with an 11% reduced risk of myocardial
infarction, a 12% reduction in the risk of any
diabetes complications, and a 13% reduction in
the risk for microvascular disease [8]. In
addition, the 7–9% reduction in body weight
in Look AHEAD was also associated with a
2–5 mg/dL increase in high-density lipoprotein
cholesterol (HDL-C), and a 4–7 mg/dL decrease
in low-density lipoprotein cholesterol (LDL-C)
[7]. For reference, note that a 23-mg/dL decrease
in total cholesterol (TC) can reduce the risk of
coronary heart disease by up to 30% [9–12].
Thus, significant improvements in CV risk
factors may be achieved through modest
reductions in body weight.
The Look AHEAD study was terminated early
based on the results of an interim analysis [13].
It was determined that the rate of severe CV
events in the treatment group (intensive
lifestyle intervention) was not significantly
different from that in the control group
(diabetes support and education) and that
given the 11-year study duration, this was not
likely to change. Although the intensive
lifestyle intervention has been discontinued,
patients will continue with follow-up as a
means of assessing any potential long-term
effects of the intervention, for example,
through metabolic memory (the ‘legacy
effect’). The results of the long-term follow-up
of patients participating in Look AHEAD will
help to more specifically inform treatment
decisions related to lifestyle intervention.
Clinically significant weight loss is
potentially within the pharmacologic effect of
GLP-1RAs (Fig. 1). In clinical trials, weight loss
with exenatide [14–17] and liraglutide have
generally ranged from 2% to 4% of initial
body mass (Table 1) [14–54]. The Liraglutide
Effect and Action in Diabetes (LEAD) trials
showed that up to one-quarter of patients lost
[5% of body weight over 26 weeks [55].
Patients participating in clinical trials of
linagliptin, saxagliptin, and sitagliptin have
typically shown a -1% to ?1% change in
body weight (Table 1; Fig. 1), and thus these
agents are considered weight-neutral.
Considering the important benefits of weight
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loss, and conversely the increased health risks
associated with further weight gain, these
features of incretin therapies represent an
important consideration for patients with (or
at risk for developing) CV disease. This is in
contrast to several other classes of therapy; for
example, the use of insulin, sulfonylureas (SUs),
and thiazolidinediones is associated with
weight gain. Although it has not been
demonstrated that the magnitude of weight
gain associated with any antihyperglycemic
therapy leads to a significant increase in the
risk of CV disease/events, it nevertheless
remains an essential goal of therapy for
patients with type 2 diabetes to achieve some
degree of weight loss—or at the very least to
prevent further weight gain [56]. In settings in
which agents that induce weight gain must be
used (for example, as the result of driving
factors such as tolerance or medication
history), the concomitant use of incretin-based
therapies should be considered as a means to
minimize additional weight gain.
In this regard, several studies have
demonstrated the weight-mitigating effects of
incretin therapies when used in conjunction
with insulin. As a recent example, Lind et al.
[57] examined the effects of adding exenatide
(n = 21) or liraglutide (n = 40) to the
antihyperglycemic regimen of patients taking
insulin and permissibly other oral antidiabetic
drugs (OADs). Most patients (69%) were taking
metformin and multiple daily insulin injections
(53%); fewer were taking a basal insulin only
(34%) or an SU (2%). After a mean of 7 months,
weight decreased by 7 kg (15 lbs; 6% of initial
Fig. 1 Weight change with incretin therapies as a function
of baseline body weight. Data correspond to the studies
described in Table 1. Data shown for DPP-4 inhibitors
(solid triangles) and GLP-1RAs (open circles). GLP-1RA
glucagon-like peptide-1 receptor agonists, DPP-4 dipeptidyl
peptidase-4
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in kg (% body weight)
GLP-1RA
Liraglutide LEAD-1: Lira 1.8 mg ? SU 83 -0.2 (-0.2)
Marre et al. [18] Rosi ? SU 81 ?2.1 (?2.6)
LEAD-2: Lira 1.8 mg ? Met NR -2.8
Nauck et al. [19] Placebo comparator -1.5
SU comparator ?1.0
LEAD-3: 1.8-mg Lira monotherapy 93 With nausea[7 days: -3.4 (-3.6)
Garber et al. [20] With nausea B7 day: -2.3 (-2.4)
SU comparator 93 With nausea[7 days: -1.4 (-1.5)
With nausea B7 days: ?1.2 (?1.3)
LEAD-4: Lira 1.8 mg ? Met ? TZD NR -2.0
Zinman et al. [21] Placebo comparator ?0.6
LEAD-5: Lira 1.8 mg ? Met ? SU 86 -1.8 (-2.1)
Russell-Jones et al. [22] Placebo comparator 86 -0.42 (-0.49)
Insulin glargine comparator 85 ?1.6 (?1.9)
LEAD-6: Lira 1.8 mg 93 -3.2 (-3.4)
Buse et al. [23] Exe comparator 93 -2.9 (-3.1)
Exenatide DURATION-1: Exe once weekly 103 -4.1 (-4.0)
Buse et al. [24] Exe twice daily switch to once weekly 102 -4.5 (-4.4)
DURATION-2: Exe once weekly 89 -2.3 (-2.6)
Bergenstal et al. [25] Sita 100 mg 87 -0.8 (-0.9)
Pio 88 ?2.8 (?3.0)
DURATION-3: Exe once weekly 91 -2.6 (-2.9)
Diamant et al. [26] Insulin glargine 91 ?1.4 (?1.5)
DURATION-4: Exe once weekly 88 -2.0 (-2.3)
Russell-Jones et al. [27] Met 86 -2.0 (-2.3)
Pio 86 ?1.5 (?1.7)
Sita 89 -0.8 (-0.9)
DURATION-5: Exe once weekly 97 -2.3 (-2.4)
Blevins et al. [28] Exe twice daily 94 -1.4 (-0.5)
Apovian et al. [29] Exe 10 lg ? Met ? SU ? LM 95 -6.2 (-6.5)
Placebo ? Met ? SU ? LM 95 -4.0 (-4.2)
Bunck et al. [30] Exe 10–20 lg 91 -3.6 (-4.0)
Insulin glargine comparator 92 ?1.0 (?1.1)
Buse et al. [15] Exe 10 lg ? SU 95 -1.6 (-1.7)
Placebo comparator
Davies et al. [31] Exe 10 lg 101 –2.7 (–2.7)
Insulin glargine 98 ?3.0 (?3.1)
DeFronzo et al. [16] Exe 10 lg ? Met 101 -2.8 (-2.8)
Placebo comparator
Gallwitz et al. [32] Exe 10 lg ? Met NR -4.1
Insulin aspart 70/30 ? Met ?1.0
Glass et al.a [33] Exe twice daily ? Met ? SU 87 -2.3 (-2.6)
Insulin (glargine or aspart) ?
Met ? SU
86 ?1.8 (2.1)
Heine et al. [14] Exe 10 lg 88 -2.3 (-2.6)
Insulin glargine comparator 88 ?1.8 (?2.0)
Kendall et al. [17] Exe 10 lg ? Met ? SU 98 -1.6 (-1.6)
Placebo comparator






in kg (% body weight)
Klonoff et al. [34] Exe ? multipleb: 3 years NR BMI\30: -3.9
BMI C30: -5.8
Moretto et al. [35] Exe 10 lg 86 -3.1 (-3.6)
Placebo comparator 86 -1.4 (-1.6)
Nauck et al. [36] Exe 10 lg ? Met ? SU 86 -2.5 (-2.9)




Sitagliptin Raz et al. [37] Sita 100 mg 93 -0.6 (-0.6)
Placebo 90 -0.7 (-0.8)
Aschner et al. [38] Sita 100 mg 85 -0.2 (-0.2)
Placebo 85 -1.1 (-1.3)
Nauck et al. [39] Sita 100 mg ? Met 90 -1.5 (-1.7)
Glipizide ? Met 90 ?1.1 (?1.2)
Wainstein et al. [40] Sita 50 mg ? Met 500 mg
FDC twice daily
83 -1.4 (1.7)
Pio 81 ?3.0 (3.7)




Sita ? Met 83 -1.1 (-1.3)
Pio 82 ?3.4 (?4.1)




Saxagliptin Rosenstock et al. [44] Saxa 5 mg 90 -0.23 (-0.3)
Placebo 93 -1.03 (-1.1)
Chacra et al. [45] Saxa 5 mg ? SU 76 ?0.8 (?1.1)
Placebo ? SU 76 ?0.3 (?0.4)
Jadzinsky et al. [46] Saxa 5 mg ? Met 82 -1.8 (-2.2)
Met monotherapy 83 -1.6 (-1.9)
DeFronzo et al. [47] Saxa 5 mg ? Met 87 -0.87 (-1.0)
Placebo ? Met 87 -0.92 (-1.1)
Linagliptin Del Prato et al. [48] Lina 5 mg 79 NR; NS
Placebo 79 NR; NS
Taskinen et al. [49] Lina 5 mg ? Met 82 -0.4 (-0.5)
Placebo ? Met 83 -0.5 (-0.6)
Owens et al. [50] Lina 5 mg ? SU 77 ?0.3 (?0.4)
Placebo ? SU 77 -0.1 (-0.1)
Haak et al. [51] Lina 5 mg 79 ?0.2 (?0.3)
Met 1,000 mg twice daily 80 -0.5 (-0.6)
Lina 2.5 mg ? Met 1,000 mg
twice daily
77 -0.8 (-1.0)
Placebo 77 -0.7 (-0.9)
Gomis et al. [52] Pio 83 ?1.3 (1.6)
Lina 5 mg ? Pio 78 ?2.7 (3.5)
Gomis et al. [53]c Lina 5 mg ? multiple: 2 years 79 -0.03 (0.04)
Gallwitz et al. [54] Lina 5 mg ? Met 86 -1.4 (1.6)
SU ? Met 87 ?1.3 (1.5)
BMI body mass index, Exe exenatide, FDC ﬁxed-dose combination, GLP-RA glucagon-like peptide-1 receptor agonist, Lina linagliptin, Lira liraglutide, LM lifestyle
management, Met metformin, NR not reported, NS non-signiﬁcant, Pio pioglitazone, Rosi rosiglitazone, Sita sitagliptin, Saxa saxagliptin, SU sulfonylurea,
TZD thiazolidinedione
a Glass et al.: pooled data from Nauck et al. [36] and Heine et al. [14]
b Klonoff et al.: patients from Buse et al. [15], DeFronzo et al. [16], and Kendall et al. [17], continued in an extension study
c Gomis et al.: patients from Del Prato et al. [48], Taskinen et al. [49], Owens et al. [50], and Gomis et al. [52] continued in an extension study
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body weight), and daily insulin doses decreased
by 39 units. The mean glycosylated hemoglobin
(HbA1c) decreased from 8.9% to 7.9%. Taken
together, the results of this study demonstrated
that the combined use of incretin therapy and
insulin is more advantageous than insulin
alone. This strategy was equally effective for
glycemic control, lower doses of insulin were
needed and, rather than gaining weight as
would be expected with initiation of insulin
therapy, patients actually lost weight.
Blood Pressure
The effects of incretin therapies on other CV
risk factors and on immediate cardiac outcomes
are subjects of ongoing research, but evidence
to date has demonstrated a favorable effect on
several variables. For example, in an analysis of
six trials, including more than 2,000 patients
treated with exenatide, the mean placebo-
adjusted SBP reduction was -2.8 mmHg [58].
Patients with baseline SBP C130 mmHg showed
mean SBP reductions of -3.8 mmHg. A more
recent meta-analysis by Vilsbøll et al. [59]
reviewed the literature on twice-daily
exenatide and liraglutide, demonstrating that
SBP reductions in published studies range from
1 to 6 mmHg. This included analysis of the
pivotal trials of exenatide [24–28] and
liraglutide [18–23], in which the mean SBP was
typically recorded as a secondary outcome.
Comparable or better results may be expected
with once-weekly exenatide; in a trial that
compared once-weekly exenatide with the
original twice-daily formulation, the mean SBP
reductions from baseline were -2.9 and
-1.2 mmHg, respectively [28]. Multiple meta-
analyses have recently been conducted in
review of the CV effects of DPP-4 inhibitors
[60–64]. In these reports, the mean change in
SBP was generally in the range of 1–4 mmHg for
linagliptin [61] and saxagliptin [60].
The mechanism by which these agents
reduce BP is not yet clear. One retrospective
analysis combined data from three exenatide
trials (N = 686 patients) to assess the
relationship among SBP reduction, weight loss,
and glycemic control [65]. This study utilized a
method of internal referencing, whereby
patients were categorized into groups
according to those achieving HbA1c reduction
and weight loss greater or less than the
weighted mean. Patients above the weighted
mean for HbA1c reduction, weight loss, or both
had, respectively, 30%, 61%, and 88% higher
chances of lowering SBP \130 mmHg
(compared with those below the mean). This
suggests that blood glucose-lowering and
weight loss may contribute independently to
BP-lowering, with synergism when both factors
are combined; however, at this time, such
interpretation is still preliminary and requires
further study as other unknown factors may
also contribute. One recent study in 61 patients
receiving exenatide for a mean of 1.4 years
evaluated the correlation between weight loss
and SBP reduction and concluded that the BP
reduction was not significantly associated with
weight loss [66].
Lipids
One study reported a significant improvement
in fasting TC and HDL-C with exenatide
therapy [67], which is consistent with an
earlier report that demonstrated significant
improvements in fasting TG and TC, HDL-C,
and LDL-C with this agent [34]. Postprandial
measurements have also shown lipid
improvement with exenatide; Meier et al. [68]
reported a non-significant increase in
postprandial TG (-0.023 mmol/L) versus
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baseline, compared with a significant
?0.33 mmol/L increase in the placebo group.
Other exenatide studies have shown no
significant change in lipid parameters [15, 16,
29, 35]. Liraglutide therapy has been shown to
improve TC and LDL-C and to significantly
decrease fasting TG by up to 36 mg/dL [69, 70].
One of the pivotal liraglutide phase 3 studies
(LEAD-6) directly compared exenatide and
liraglutide, including analysis of lipid
parameters [23]. Relative to exenatide,
liraglutide led to a similar reduction in TC
(-0.2 versus -0.1 mmol/L), LDL-C (-0.5
versus -0.4 mmol/L), and TG (-0.4 versus
-0.2 mmol/L).
A recent meta-analysis of the literature on
DPP-4 inhibitors specifically evaluated the
effects of these agents on lipid parameters [64].
This analysis concluded that treatment with
DPP-4 inhibitors was associated with significant
improvements in TG (-0.1 mmol/L), but not
HDL-C. Although an overall significant
reduction in TC (-0.2 mmol/L) was
determined, evaluation of DPP-4 inhibitors on
an individual basis suggested that the US-
approved agents had no significant effect on
TC. This report did not include data on
linagliptin, although another meta-analysis by
Johansen et al. [61] included an assessment of
lipid data reported in published linagliptin
studies. Linagliptin reduced TG by 0.1 mmol/L
from baseline (P value not reported) and did not
appear to influence TC.
CARDIOVASCULAR EVENTS
The effect of DPP-4 inhibitors on the occurrence
of CV events has been retrospectively evaluated
by meta-analysis [60–63]. Monami et al. [62]
reviewed 33 placebo-controlled studies of DPP-4
inhibitors and, as part of their analysis,
included an assessment of CV events. These
authors reported an odds ratio (OR) for CV
events of 1.04 (0.70–1.55) versus placebo for
patients taking a DPP-4 inhibitor. Meta-analyses
of individual DPP-4 inhibitors have
demonstrated ORs for CV events of 0.43 [95%
confidence interval (CI) 0.23, 0.80] for
saxagliptin [60], and 0.34 (95% CI 0.16, 0.70)
for linagliptin [61]. While not drawn from
prospective studies powered to specifically
evaluate such outcomes, these ORs represent a
significant reduction in the risk of CV events
and merit further investigation.
To this end, several prospective clinical trials
are currently in progress. The CAROLINA study
(Cardiovascular Outcome Study of Linagliptin
versus Glimepiride in Patients with Type 2
Diabetes; NCT01243424) has a targeted
enrollment of *6,000 patients with type 2
diabetes. With a planned duration of up to
8 years, this study will investigate the long-term
impact of treatment with linagliptin on CV
morbidity and mortality in patients with type 2
diabetes who are at an elevated CV risk and
compare the outcome against treatment with
the SU glimepiride. Comparable trials are also in
progress for other DPP-4 inhibitors. The TECOS
study (Trial Evaluating Cardiovascular
Outcomes With Sitagliptin; NCT00790205)
will compare the impact of usual care with
and without add-on sitagliptin on CV outcomes
in an estimated 14,000 patients followed for up
to 5 years. SAVOR-TIMI (Saxagliptin Assessment
of Vascular Outcomes Recorded in patients with
diabetes mellitus–Thrombolysis In Myocardial
Infarction; NCT01107886) enrolled 16,496
diabetic patients with either established CV
disease or at high risk for CV events, and
compared a primary composite CV endpoint
in patients taking saxagliptin for up to 5 years
versus placebo [71]. Data show that the primary
non-inferiority safety endpoint has been met;
saxagliptin does not increase CV events
228 Diabetes Ther (2013) 4:221–238
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compared with placebo when added to the
patient’s standard-of-care regimen (with or
without other antidiabetic medications). Since
results did not show a decrease in the risk of
overall CV events with saxagliptin versus
comparators, the trial did not meet the
primary efficacy objective of superiority [72].
When fully available, these studies will
provide long-term data on the CV effects of
DPP-4 inhibitors in patients with type 2
diabetes. These data will address an important
need in the medical literature, particularly
considering that some data have suggested an
exacerbation of CV risk with the more
commonly prescribed SUs, especially when
used in combination with metformin. For
example, in the UKPDS study, the early
addition of metformin to an SU was associated
with a 96% increase in diabetes-related deaths
compared with continued SU use [73]. Later
studies provided additional data that described
this association. One study reported an adjusted
43% increase in total mortality and an adjusted
70% increase in CV mortality in patients taking
an SU versus metformin [74]. A retrospective
review of the UK General Practice Research
Database showed that the combination of
metformin and SU increased mortality by
24–61% (P = 0.001) and heart failure by
18–30% relative to metformin monotherapy
[75]. Meta-analyses on this subject have also
described adverse outcomes associated with SU-
metformin combination therapy [76, 77].
Considering the high prevalence of CV
mortality in patients with diabetes, the
importance of medications with favorable CV
safety profiles cannot be understated. At the
very least, medications for the treatment of
diabetes should be neutral if not actively
preventive with regard to CV risk factors and
outcomes. The current literature on incretin-
based therapies is promising in this respect and,
in the coming years, we can expect the CV
literature to provide a more detailed view of
these and other antidiabetic therapies.
SUSTAINABILITY
OF THE PRESCRIBED REGIMEN
Discontinuation of adherence to prescribed
therapies remains an important obstacle to
achieving treatment goals in patients with
type 2 diabetes. Intolerability is the most
common factor leading to medication
discontinuation [e.g., hypoglycemia,
gastrointestinal (GI) disturbances], although
other factors such as natural history, complex
daily regimens, out-of-pocket costs, and
declining efficacy may also play a role. For
example, a survey-based study of 2074 patients
with type 2 diabetes found that over a 2-week
period, 57% of participants reported symptoms
of hypoglycemia, 28% reported constipation or
diarrhea, and 21–26% experienced headaches,
water retention, or weight gain. The important
finding from this study in relation to adherence
was that each additional tolerability issue was
associated with a 28% increase in medication
non-adherence [78].
Hypoglycemia
Hypoglycemia is one of the more common
tolerability/side effect issues leading to
medication discontinuation. Incretin-based
therapies induce the secretion of insulin from
pancreatic tissue only in the presence of
elevated blood glucose (e.g., ‘glucose-
dependent insulin secretion’); these agents
therefore pose a low risk for hypoglycemia. A
recent claims database analysis specifically
examined hypoglycemic events in more than
212,000 patients taking OADs from January
1999 through September 2008 [79]. The rates
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of hypoglycemia were significantly increased in
patients taking SU compared with those not
receiving SU [hazard ratio, 1.58 (1.51, 1.65)],
were significantly decreased in patients taking a
DPP-4 inhibitor versus those not taking a DPP-4
inhibitor [OR 0.79 (0.65, 0.95)], and were not
significantly different between patients taking
metformin versus those not taking metformin.
Importantly, the incidence of at least one
hypoglycemic event was associated with
medication discontinuation. In this study,
medication discontinuation was determined as
a gap of C30 days within a 6-month interval
following the hypoglycemic event. Compared
with patients with no hypoglycemic events, in
those who had one or more episodes, the OR for
medication discontinuation was 1.26 (1.22,
1.31). Given the low rates of hypoglycemia
associated with incretin-based therapies, these
agents may serve to improve medication
adherence in patients with intolerability issues
related to hypoglycemia.
Medication Adherence Rates
Although the specific metric of medication
adherence may vary across studies, the
consensus perspective evident in the literature
is that a large proportion of patients do not
continue to take the antihyperglycemic
medications prescribed by their physicians for
the long term. Two of the largest studies
exploring medication adherence utilized the
Veterans Administration (VA) database. In a
study of records from more than 56,000
veterans with type 2 diabetes taking OADs
(years 2000–2002), 23% of patients were
categorized as non-adherent, as defined by a
medication possession ratio (MPR) \80% after
1 year [80]. A later re-evaluation of the VA
database (years 2005–2007) demonstrated a
somewhat higher rate of non-adherence (30%)
using the 1-year MPR (N = 444,418) [81]. One
study that reviewed the medical literature for
data on adherence (years 2000–2005) reported
similar results, showing that 42% of patients
had a 1-year MPR\80% (35 studies) [82]. Based
on only these results, one might conclude that
approximately one-third of patients with type 2
diabetes can be expected to take less than 80%
of their prescribed medication. A more recent
study of patients taking exenatide (n = 3,262)
compared adherence rates with patients taking
insulin glargine (n = 3,038) [83]. Using the
1-year MPR, 32% of patients taking exenatide
and 42% taking glargine were categorized as
non-adherent.
Although there are no studies that
specifically evaluate adherence rates in
patients taking DPP-4 inhibitors, several
publications have reviewed the
discontinuation and adverse event (AE) rates
of these agents in clinical trials. For example,
Karagiannis et al. [84] reported that AE-related
discontinuation rates in trials of DPP-4
inhibitors (nine sitagliptin studies, six
vildagliptin studies, three saxagliptin studies,
and one linagliptin study) were lower than in
patients taking metformin monotherapy
(relative risk 0.69, 0.51–0.94). Recently, Singh-
Franco et al. [85] reported another meta-
analysis that included an assessment of
discontinuation rates in five published and
four unpublished trials of linagliptin. The
overall rate of AEs in this analysis was not
significantly different from placebo, nor were
withdrawals due to AEs significantly different
between linagliptin (2.4%) and placebo (3.1%),
which is consistent with the results of another
meta-analysis of linagliptin trials [85, 86]. A
pooled analysis of data from sitagliptin trials
(N = 10,246 patients with type 2 diabetes)
showed that the rates of discontinuation due
to AEs were similar in patients receiving
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sitagliptin versus comparators (4.4% versus
4.5%, respectively) [87]. These results are
consistent with data from meta-analyses and
systematic reviews showing an acceptable safety
and tolerability profile for DPP-4 inhibitors [63,
84].
Within the incretin-mimetics class, the most
commonly occurring tolerability issue stems
from GI side effects (e.g., nausea, abdominal
discomfort, and vomiting) [88]. These may
occur in up to 30% of patients, although the
incidence of GI symptoms usually declines
within the first month of therapy [89–91]. No
studies have yet been published that describe
adherence rates in patients taking the recently
approved once-weekly formulation of
exenatide. However, provided that the
efficacy, AE profile, and rate of
discontinuation of the once-weekly
formulation is not significantly different from
the older twice-daily formulation [92], it may be
expected that patient adherence to the once-
weekly formulation may be improved as a result
of its simpler dosing schedule.
Lastly, it has been shown that simplification
of the dosing schedule can lead to significant
improvements in medication adherence using
fixed-dose combination (FDC) therapies. For
example, a retrospective database review
recently showed that patients with diabetes
who were categorized by their physicians as
adherent to their prescribed antihyperglycemic
medication regimen were five times more likely
to be taking an FDC than those who were
described by physicians as non-adherent [93].
Initiation of treatment with an FDC is
associated with greater adherence when
compared with patients receiving the same
medications as ‘loose-pill combination.’
Authors of an analysis of seven studies that
compared these strategies concluded that
adherence was 13% greater in patients who
started on FDCs [94]. Cheong et al. [95]
demonstrated that when patients already
taking loose-pill combinations (N = 14,762)
were switched to a comparable FDC
(N = 7,570), adherence increased by 12%.
Each of the four Food and Drug
Administration-approved DPP-4 inhibitors has
been developed with an FDC formulation
(combination with metformin). Thus, when
considered along with their excellent
tolerability profiles, the availability of FDCs
with these agents proffers a means of
increasing medication adherence in patients
with type 2 diabetes.
CONCLUSION
Diabetes is a multifactorial disease with a
high prevalence of comorbidities resulting
from hypertension, dyslipidemia, and
hyperglycemia. Inadequate management of
these three physiologic risk factors in patients
with type 2 diabetes will eventually lead to a
debilitating loss of function in multiple organ
systems. Therefore, each of these risk factors
must be brought under control as early as
possible following diagnosis, and their control
must be maintained throughout the course of
the disease. Emphasis in the medical literature
has tended to focus on glycemic control, in part
due to the rapid expansion of the number of
antidiabetic agents that require evaluation of
efficacy. However, in recent years, it has become
evident that key pharmacologic characteristics
of antihyperglycemic medications reach
beyond an effect on blood glucose. The
assessment of new medications for the
treatment of type 2 diabetes is now more
comprehensive than in the earlier decades of
OAD research. The GLP-1RA and the DPP-4
inhibitors are the first classes of new
antidiabetes treatments that needed
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demonstration of CV safety as a regulatory
approval requirement. Moreover, long-term
safety trials are in progress, with results from
the first studies showing no increase in overall
CV risk [72, 96]. Thus, we have at our disposal a
wealth of information describing the range of
actions of glucose-lowering medications in
patients with type 2 diabetes.
Guidelines from the American Diabetes
Association and the American Association of
Clinical Endocrinologists (AACE) stress an
individualized approach to care, which
includes consideration of patient preferences,
medication cost, potential class-related side
effects, and the effects of treatments on body
weight and hypoglycemia risk [56, 97]. In the
AACE algorithm, GLP-1RA and DPP-4 inhibitors
are recommended after metformin based on
their therapeutic profiles indicating few AEs or
possible benefits [97]. For GLP-1RA, added
benefits include weight loss, improvement in
BP, and a decrease in inflammatory markers.
The side effect profile for GLP-1RAs, however,
can be difficult for some patients because of the
potential for nausea, and even vomiting.
Patients also may be resistant to an injectable
therapy. For DPP-4s, benefits include oral
administration with good patient acceptance
and an excellent tolerability profile, resulting in
few patient requests to switch therapy. When
discussing therapy options, a patient-centered
communication style focused on the patient’s
foremost problems and how they are feeling
physically is important [98]. Clinicians can use
practical terms about how incretin therapy
options address patient concerns, such as fear
of weight gain with add-on therapy. The
underlying mechanisms of incretin-based
therapies may represent a novel approach to
the management of type 2 diabetes, given that
these agents may act through multiple signaling
pathways to effect changes not only in glucose
homeostasis, but possibly in other physiologic
processes as well. For example, there is some
evidence that GLP-1 receptors may have a direct
influence in BP regulation and other cardiac
functions [99]. In addition, whether GLP-1RAs
and DPP-4 inhibitors have a direct effect on
blood lipids seems an unanswered question,
with some studies reporting null and others
significant results. However, in the near future,
we may expect a clearer understanding of these
extraglycemic effects of incretin therapies and,
for the time being, our task is to tailor best
practices to fit the current evidence.
The synthesis resulting from this review of
the literature yields two main conclusions about
the extraglycemic effects of incretin therapies.
In addition to their well-known influence on
the maintenance or loss of weight, the use of
GLP-1RAs and DPP-4 inhibitors appears to be
associated with a modest decrease in BP and a
reduced risk for CV events. Secondly, several
characteristics of incretin therapies may
improve rates of medication adherence such as
the availability of formulations that simplify
treatment regimens (e.g., once-weekly
exenatide, DPP-4/metformin FDCs), a low risk
for hypoglycemia, and generally favorable
tolerability profiles, particularly with DPP-4
inhibitors.
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